Oromucosal midazolam

Key words: Oromucosal midazolam, Seizures, Clinical trials, Licensed use

Oromucosal midazolam (Buccolam) has been recently approved also in Italy for the treatment of paediatric patients (aged 3 months to <18 years) with Dravet and Panayiotopoulos syndrome and with previous acute, prolonged, convulsive seizures (> 5 minutes). Oromucosal midazolam was at least as effective as rectal diazepam in clinical trials in children with prolonged, acute, convulsive seizures and as effective as intravenous diazepam in the treatment of seizures and was generally well tolerated. It has several advantages over rectal diazepam, the previous gold standard of treatment, such as a more convenient and socially acceptable administration route.